bluuebunny/crossref_metadata_2025_split huggingface dataset:
Repurposing CRISPR/Cas to Discover SARS‐CoV‐2 Detecting and Neutralizing Aptamers
Authors: Zhang Ju , Zhu Airu , Mei Miao , Qu Jing , Huang Yalan , Shi Yongshi , Xue Meiying , Zhang Jingfang , Zhang Renli , Zhou Bing , Tan Xu , Zhao Jincun , Wang Yu 
Published: May 2023

AbstractRNA aptamers provide useful biological probes and therapeutic agents. New methodologies to screen RNA aptamers will be valuable by complementing the traditional Systematic Evolution of Ligands by Exponential Enrichment (SELEX). Meanwhile, repurposing clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated systems (Cas) has expanded their utility far beyond their native nuclease function. Here, CRISmers, a CRISPR/Cas‐based novel screening system for RNA aptamers based on binding to a chosen protein of interest in a cellular context, is presented. Using CRISmers, aptamers are identified specifically targeting the receptor binding domain (RBD) of the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Two aptamer leads enable sensitive detection and potent neutralization of SARS‐CoV‐2 Delta and Omicron variants in vitro. Intranasal administration of one aptamer, further modified with 2’‐fluoro pyrimidines (2’‐F), 2’‐O‐methyl purines (2’‐O), and conjugation with both cholesterol and polyethylene glycol of 40 kDa (PEG40K), achieves effective prophylactic and therapeutic antiviral activity against live Omicron BA.2 variants in vivo. The study concludes by demonstrating the robustness, consistency, and potential broad utility of CRISmers using two newly identified aptamers but switching CRISPR, selection marker, and host species.
Ameliorating Mitochondrial Dysfunction of Neurons by Biomimetic Targeting Nanoparticles Mediated Mitochondrial Biogenesis to Boost the Therapy of Parkinson's Disease
Authors: Zheng Qing , Liu Hanghang , Zhang Hao , Han Yaobao , Yuan Jiaxin , Wang Tingting , Gao Yifan , Li Zhen 
Published: May 2023

AbstractMitochondrial dysfunction of neurons is the core pathogenesis of incurable Parkinson's disease (PD). It is crucial to ameliorate the mitochondrial dysfunction of neurons for boosting the therapy of PD. Herein, the remarkable promotion of mitochondrial biogenesis to ameliorate mitochondrial dysfunction of neurons and improve the treatment of PD by using mitochondria‐targeted biomimetic nanoparticles, which are Cu2‐xSe‐based nanoparticles functionalized with curcumin and wrapped with DSPE‐PEG2000‐TPP‐modified macrophage membrane (denoted as CSCCT NPs), is reported. These nanoparticles can efficiently target mitochondria of damaged neurons in an inflammatory environment, and mediate the signaling pathway of NAD+/SIRT1/PGC‐1α/PPARγ/NRF1/TFAM to alleviate 1‐methyl‐4‐phenylpyridinium (MPP+)‐induced neuronal toxicity. They can reduce the mitochondrial reactive oxygen species, restore mitochondrial membrane potential (MMP), protect the integrity of mitochondrial respiratory chain, and ameliorate mitochondrial dysfunction via promoting mitochondrial biogenesis, which synergistically improve the motor disorders and anxiety behavior of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced PD mice. This study demonstrates that targeting mitochondrial biogenesis to ameliorate mitochondrial dysfunction has a great potential in the treatment of PD and mitochondria‐related diseases.
Sodium Rich Vanadium Oxy‐Fluorophosphate – Na3.2Ni0.2V1.8(PO4)2F2O – as Advanced Cathode for Sodium Ion Batteries
Authors: Essehli Rachid , Yahia Hamdi Ben , Amin Ruhul , Li Mengya , Morales Daniel , Greenbaum Steven G. , Abouimrane Ali , Parejiya Anand , Mahmoud Abdelfattah , Boulahya Khalid , Dixit Marm , Belharouak Ilias 
Published: May 2023

AbstractConventional sodium‐based layered oxide cathodes are extremely air sensitive and possess poor electrochemical performance along with safety concerns when operating at high voltage. The polyanion phosphate, Na3V2(PO4)3 stands out as an excellent candidate due to its high nominal voltage, ambient air stability, and long cycle life. The caveat is that Na3V2(PO4)3 can only exhibit reversible capacities in the range of 100 mAh g−1, 20% below its theoretical capacity. Here, the synthesis and characterizations are reported for the first time of the sodium‐rich vanadium oxyfluorophosphate, Na3.2Ni0.2V1.8(PO4)2F2O, a tailored derivative compound of Na3V2(PO4)3, with extensive electrochemical and structural analyses. Na3.2Ni0.2V1.8(PO4)2F2O delivers an initial reversible capacity of 117 mAh g−1 between 2.5 and 4.5 V under the 1C rate at room temperature, with 85% capacity retention after 900 cycles. The cycling stability is further improved when the material is cycled at 50 °C within 2.8–4.3 V for 100 cycles. When paired with a presodiated hard carbon, Na3.2Ni0.2V1.8(PO4)2F2O cycled with a capacity retention of 85% after 500 cycles. Cosubstitution of the transition metal and fluorine in Na3.2Ni0.2V1.8(PO4)2F2O as well as the sodium‐rich structure are the major factors behind the improvement of specific capacity and cycling stability, which paves the way for this cathode in sodium‐ion batteries.
Enabling Stable Zn Anodes by Molecularly Engineering the Inner Helmholtz Plane with Amphiphilic Dibenzenesulfonimide Additive
Authors: Yang Jun , Han Zhiqiang , Wang Zhiqiang , Song Liying , Zhang Busheng , Chen Hongming , Li Xing , Lau Woon‐Ming , Zhou Dan 
Published: May 2023

AbstractThe notorious dendrite growth and hydrogen evolution reaction (HER) are considered as main barriers that hinder the stability of the Zn‐metal anode. Herein, molecular engineering is conducted to optimize the inner Helmholtz plane with a trace of amphiphilic dibenzenesulfonimide (BBI) in an aqueous electrolyte. Both experimental and computational results reveal that the BBI−binds strongly with Zn2+to form {Zn(BBI)(H2O)4}+in the electrical double layer and reduces the water supply to the Zn anode. During the electroplating process, {Zn(BBI)(H2O)4}+is “compressed” to the Zn anode/electrolyte interface by Zn2+flow, and accumulated and adsorbed on the surface of the Zn anode to form a dynamic water‐poor inner Helmholtz plane to inhibit HER. Meanwhile, the{Zn(BBI)(H2O)4}+on the Zn anode surface possesses an even distribution, delivering uniform Zn2+flow for smooth deposition without Zn dendrite growth. Consequently, the stability of the Zn anode is largely improved with merely 0.02 M BBI−to the common electrolyte of 1 M ZnSO4. The assembled Zn||Zn symmetric cell can be cycled for more than 1180 h at 5 mA cm−2and 5 mA h cm−2. Besides, the practicability in Zn||NaV3O8·1.5 H2O full cell is evaluated, which suggests efficient storage even under a high mass loading of 12 mg cm−2.
Hypothetical bias mitigation in representative and convenience samples
Authors: Penn Jerrod M. , Petrolia Daniel R. , Fannin J. Matthew 
Published: May 2023

AbstractThis is a case study comparing outcomes for a probability‐based representative sample versus a non‐probability convenience sample for the valuation of beach condition information among Gulf of Mexico residents. We test the efficacy of several techniques used to adjust for hypothetical bias and sample weighting to reduce hypothetical willingness to pay (WTP). Weighting makes the WTP between the two samples similar, but model equivalence with respect to the significance of explanatory variables is rejected. The results support the use of certainty follow‐ups, which consistently reduced WTP, regardless of the sampling approach or weighting.
How intention to join an Alzheimer's participant recruitment registry differs by race, ethnicity, sex, and family history: Results from a national survey of US adults
Authors: Langbaum Jessica B. , Maloney Erin , Hennessy Michael , Harkins Kristin , Karlawish Jason , Nosheny Rachel L. , Bleakley Amy 
Published: May 2023

AbstractINTRODUCTIONAlzheimer's‐focused participant recruitment registries are tools for accelerating enrollment into studies, however, registry members are primarily White women.METHODSWe conducted a national online survey of 1501 adults ages 50–80, oversampling for Black and Hispanic/Latino respondents, assessing intention to join a generic “brain health” registry and to join a registry that required specific tasks.RESULTSIntention to join a registry was low (M 3.48, SD 1.77), and lower than intention to join a registry requiring specific tasks. Intention was greatest for registries requiring completing surveys (M 4.70, SD 1.77). Differences in intention were primarily between White women and Black women; differences between other groups were limited to specific tasks required.DISCUSSIONThe results indicate uncertainty about what a registry is, its purpose, and/or the concept of “brain health.” Using the Reasoned Action Approach (RAA) to develop evidence‐based outreach messages describing a registry and required tasks may increase diversity.
APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials
Authors: Evans Cynthia D. , Sparks JonDavid , Andersen Scott W. , Brooks Dawn A. , Hauck Paula M. , Mintun Mark A. , Sims John R. 
Published: May 2023

AbstractINTRODUCTIONApolipoprotein E (APOE) ε4 may interact with response to amyloid‐targeting therapies.METHODSAggregate data from trials enrolling participants with amyloid‐positive, early symptomatic Alzheimer's disease (AD) were analyzed for disease progression.RESULTSPooled analysis of potentially efficacious antibodies lecanemab, aducanumab, solanezumab, and donanemab shows slightly better efficacy in APOE ε4 carriers than in non‐carriers. Carrier and non‐carrier mean (95% confidence interval) differences from placebo using Clinical Dementia Rating Scale–Sum of Boxes (CDR‐SB) were –0.30 (–0.478, –0.106) and –0.20 (–0.435, 0.042) and AD Assessment Scale–Cognitive subscale (ADAS‐Cog) values were –1.01 (–1.577, –0.456) and –0.80 (–1.627, 0.018), respectively. Decline in the APOE ε4 non‐carrier placebo group was equal to or greater than that in carriers across multiple scales. Probability of study success increases as the representation of the carrier population increases.DISCUSSIONWe hypothesize that APOE ε4 carriers have same or better response than non‐carriers to amyloid‐targeting therapies and similar or less disease progression with placebo in amyloid‐positive trials.HIGHLIGHTS
Amyloid‐targeting therapies had slightly greater efficacy in apolipoprotein E (APOE) ε4 carriers.
Clinical decline is the same/slightly faster in amyloid‐positive APOE ε4 non‐carriers.
Prevalence of non‐carriers in trial populations could impact outcomes.
Dynamikuntersuchungen des Wachstumshormon‐Sekreteagogum‐Rezeptors geben Einblicke in seine Energielandschaft
Authors: Smith Albert A. , Pacull Emelyne M. , Stecher Sabrina , Hildebrand Peter W. , Vogel Alexander , Huster Daniel 
Published: May 2023

AbstractG‐Protein‐gekoppelte Rezeptoren initiieren die Signaltransduktion nach Ligandenbindung. Gegenstand der Studie ist der Wachstumshormon‐Sekreteagogum‐Rezeptor (GHSR), der durch das Peptid Ghrelin aktiviert wird. Obwohl es Strukturen des GHSR in verschiedenen Stadien der Aktivierung gibt, wurde die molekulare Dynamik dieser Zustände bisher nicht beschrieben. Wir analysierten die Trajektorien von Molekulardynamiksimulationen mittels Detektoranalyse, um die Dynamik des Apo‐ und des Liganden‐gebundenen Zustands zu vergleichen. Diese Analyse liefert zeitskalenspezifische Bewegungsamplituden. Wir identifizierten Unterschiede in der Dynamik des Apo‐ und Ghrelin‐gebundenen Zustands, insbesondere in der extrazellulären Schleife 2 und den Transmembranhelices 5–7. Kernresonanz‐Spektren der Histidinreste im GHSR zeigten Unterschiede in den chemischen Verschiebungen dieser Regionen. Wir evaluierten zeitskalenspezifische Korrelationen der Bewegungen zwischen Ligand und Rezeptor und fanden Korrelationen zwischen den N‐terminalen Ghrelin‐Resten und dem Rezeptor, nicht aber für den C‐Terminus von Ghrelin. Eine Hauptkomponentenanalyse lieferte Rückschlüsse auf die Energielandschaft des GHSR.
Platelet‐activating factor as an endogenous cofactor of food anaphylaxis
Authors: Pałgan Krzysztof , Tretyn Andrzej 
Published: May 2023

AbstractAnaphylaxis is a severe, acute, life‐threatening generalized or systemic hypersensitivity reaction. The incidence of anaphylaxis is increasing worldwide, with medications and food contributing to most cases. Physical exercise, acute infections, drugs, alcohol, and menstruation are the external cofactors associated with more severe systemic reaction. The aim of this review is to show that platelet‐activating factor contributes to the development of severe anaphylactic reaction, and even to anaphylactic shock.
Protein engineering, cofactor engineering, and surface display engineering to achieve whole‐cell catalytic production of chondroitin sulfate A
Authors: Liu Haoyu , Wei Wanqing , Pang Zixuan , Gu Simin , Song Wei , Gao Cong , Chen Xiulai , Liu Jia , Guo Liang , Wu Jing , Liu Liming 
Published: May 2023

AbstractChondroitin sulfate A (CSA) is a valuable glycosaminoglycan that has great market demand. However, current synthetic methods are limited by requiring the expensive sulfate group donor 3′‐phosphoadenosine‐5′‐phosphosulfate (PAPS) and inefficient enzyme carbohydrate sulfotransferase 11 (CHST11). Herein, we report the design and integration of the PAPS synthesis and sulfotransferase pathways to realize whole‐cell catalytic production of CSA. Using mechanism‐based protein engineering, we improved the thermostability and catalytic efficiency of CHST11; its Tm and half‐life increased by 6.9°C and 3.5 h, respectively, and its specific activity increased 2.1‐fold. Via cofactor engineering, we designed a dual‐cycle strategy of regenerating ATP and PAPS to increase the supply of PAPS. Through surface display engineering, we realized the outer membrane expression of CHST11 and constructed a whole‐cell catalytic system of CSA production with an 89.5% conversion rate. This whole‐cell catalytic process provides a promising method for the industrial production of CSA.
Dimensions of apathy in Parkinson's disease
Authors: Thompson Nasya , MacAskill Michael , Pascoe Maddie , Anderson Tim , Heron Campbell Le 
Published: May 2023

IntroductionApathy is one of the most common neuropsychiatric manifestations in Parkinson's disease (PD). Recent proposals consider apathy as a multidimensional construct, which can manifest in behavioral, cognitive, emotional, and/or social dimensions. Apathy also overlaps conceptually and clinically with other non‐motor comorbidities, particularly depression. Whether all of these dimensions are applicable to the apathetic syndrome experienced by people with PD is unclear. In the present study, we investigated the multidimensional pattern of apathy associated with PD, using the recently developed Apathy Motivation Index (AMI) which probes behavioral, emotional, and social apathy dimensions. We then examined the relationship between these dimensions and other features of PD commonly associated with apathy, including depression, anxiety, cognition, and motor state.MethodsA total of 211 participants were identified from the New Zealand Brain Research Institute (NZBRI) longitudinal PD cohort. One hundred eight patients and 45 controls completed the AMI, administered as an online questionnaire, and additional assessments including neuropsychiatric, neuropsychological, and motor scores. The pattern of dimensional apathy in PD was assessed using a repeated‐measured analysis of variance, while simple linear regressions were performed to evaluate relationships between these dimensions and other variables.ResultsWe found a significant interaction between group (PD versus control) and apathy subscale, driven mainly by higher levels of social and behavioral—but not emotional—apathy in those with PD. This result was strikingly similar to a previous study investigating social apathy in PD. Distinct patterns of dimensional apathy were associated with depression and anxiety, with social and behavioral apathy positively associated with depression, and emotional apathy negatively associated with anxiety.ConclusionThis work provides further evidence for a distinct pattern of apathy in people with PD in which deficits manifest in some—but not all—dimensions of motivated behavior. It emphasizes the importance of considering apathy as a multidimensional construct in clinical and research settings.
Bibliometric and visualized analysis of applying tumor markers in lung cancer diagnosis from 2000 to 2022
Authors: Ke Shi‐Peng , Chen Si‐Mei , Jiang Yi , Gong Heng‐Xin , Yu Jia‐Li , Li Xu , Chen Yin‐Yi , Li Xiao‐Hang , Wang Qun‐Xia , Liu Yan‐Zhao 
Published: May 2023

AbstractBackgroundLung cancer (LC) is the leading cause of cancer‐related deaths worldwide. Tumor marker (TM) detection can indicate the existence and growth of a tumor and has therefore been used extensively for diagnosing LC. Here, we conducted a bibliometric analysis to examine TM‐related publications for LC diagnosis to illustrate the current state and future trends of this field, as well as to identify additional promising TMs with high sensitivity.MethodsPublications regarding TMs in LC diagnosis were downloaded from the Web of Science Core Collection. CiteSpace was applied to perform a bibliometric analysis of journals, cocitation authors, keywords, and references related to this field. VOSviewer was used to generate concise diagrams about countries, institutions, authors, and keywords. Changes in the TM research frontier were analyzed through citation burst detection.ResultsA total of 990 studies were analyzed in this work. The collaboration network analysis revealed that the People's Republic of China, Yonsei University, and Molina R were the most productive country, institution, and scholar, respectively. Additionally, Molina R was the author with the most citations. The National Natural Science Foundation of China was the largest funding source. “Carcinoembryonic antigen (CEA) as tumor marker in lung cancer” was the top reference with the most citations, Lung Cancer was the core journal, and “serum tumor marker” experienced a citation burst over the past 5 years.ConclusionThis bibliometric analysis of TMs in LC diagnosis presents the current trends and frontiers in this field. We summarized the research status of this field and the methods to improve the diagnostic efficacy of traditional serum TMs, as well as provided new directions and ideas for improving the LC clinical detection rate. Priority should be given to the transformation of computer‐assisted diagnostic technology for clinical applications. In addition, circulating tumor cells, exosomes, and microRNAs were the current most cutting‐edge TMs.
PD‐1/L1 inhibitors can improve but not replace chemotherapy for advanced urothelial carcinoma: A systematic review and network meta‐analysis
Authors: Mao Longkun , Yang Meihua , Fan Xinxiang , Li Wenjie , Huang Xiaodong , He Wang , Lin Tianxin , Huang Jian 
Published: May 2023

AbstractBackgroundProgrammed cell death‐1/ligand 1 inhibitors are a new treatment strategy for advanced urothelial carcinoma. Therefore, a comparative evaluation of their efficacy and toxicity compared with chemotherapy is necessary.MethodsWe comprehensively searched PubMed, Web of Science, Embase, and Cochrane Library databases and performed a meta‐analysis of randomized controlled trials up to July 2021. We considered overall survival as the primary outcome, and progression‐free survival, objective response rate, and treatment‐related adverse events as secondary outcomes.ResultsOverall, 3584 patients from five studies were evaluated. Compared with first‐line chemotherapy, programmed cell death‐1/ligand 1 inhibitors were significantly associated with worse progression‐free survival (p < 0.001) and adverse objective response rates (p < 0.001). However, the treatments were not significantly different in terms of overall survival (p = 0.33). Compared with second‐line chemotherapy, programmed cell death‐1/ligand 1 inhibitors significantly improved overall survival (p < 0.001), and there was no statistically significant difference in progression‐free survival (p = 0.89) or objective response rate (p = 0.34). Compared with chemotherapy, programmed cell death‐1/ligand 1 inhibitors were well tolerated (first‐line chemotherapy: p < 0.001; second‐line chemotherapy: p < 0.001).ConclusionsThe efficacy of programmed cell death‐1/ligand 1 inhibitors in patients with advanced urothelial carcinoma is not superior to that of first‐line platinum‐based chemotherapy but is better than second‐line chemotherapy; however, programmed cell death‐1/ligand 1 inhibitors are safer than first‐ and second‐line chemotherapy and have a broader prospect for use in combination therapy.
Severe superior mesenteric vein thrombosis after COVID‐19 mRNA vaccination
Authors: Kubo Takahiro , Kawaratani Hideto , Yoshiji Hitoshi 
Published: May 2023

Key Clinical MessageVenous thrombosis is a rare occurrence following the administration of the COVID‐19 mRNA vaccine. The occurrence of superior mesenteric vein (SMV) is even more rare. SMV thrombosis should be considered as a differential diagnosis in patients who develop abdominal pain after COVID‐19 mRNA vaccination.
Comprehensive treatment for ROS1‐overexpressed pulmonary sarcomatoid carcinoma: A case report
Authors: Sun Wei , Wang Xinlian , Shi Qifeng , Li Xiao , Chen Chaobo 
Published: May 2023

Key Clinical MessageIn conclusion author highlights the tumor cell genetic testing or molecular pathological diagnosis plays a key role in the individualized treatment of PSC, which could benefit patients with advanced PSC.AbstractAn uncommon form of non‐small‐cell lung cancer (NSCLC) with a poor prognosis is pulmonary sarcomatoid carcinoma (PSC). Surgical resection is currently the preferred treatment, but guidelines for adjuvant chemotherapy have not yet been established, especially for the advanced stage. The development of molecular subgroups in the field of tumors may be advantageous to advanced PSC patients with the ongoing progress of genomics and immunology. A 54‐year‐old man presented to Xishan People's Hospital of Wuxi City with recurrent intermittent dry cough with fever for 1 month. Further examinations suggested the diagnosis of PSC occupying almost the entire right interlobar fissure area combined with malignant pleural effusion (Stage IVa). Pathological examination confirmed the diagnosis of PSC with ROS1 overexpressing via genetic testing. However, after three cycles of chemo‐, antiangiogenetic‐ and immunochemical therapy, the lesion was localized, and pleural effusion disappeared, the patient subsequently received an operation which was performed as R0 resection. Unfortunately, the patient became deteriorated quickly followed by extensive metastatic nodules in the thoracic cavity. Although the patient continued to receive chemo‐ and immunochemical‐therapy, it did not limit the progress of the tumor, leading to widespread metastasis, and eventually died of multiple organ failure. For PSC patients with Stage IVa, chemo‐, antiangiogenetic‐ and immunochemical‐therapy performs well in clinical efficacy, and comprehensive panel‐based genetic testing may offer PSC patients a somewhat better prognosis. However, blindly implementing surgical treatment may bring harm to the patient and affect long‐term survival. It's essential to know the surgical indications precisely by NSCLC guidelines.
Resuscitative TEE after open heart surgery: When POCUS fails to FOCUS
Authors: Higny Julien , Berners Yannick , Luchian Maria‐Luiza 
Published: May 2023

Key Clinical MessageEchocardiography is key in evaluating the cause of collapse in the post‐cardiac surgery patient. Transesophageal echocardiography provides a greater capability for the diagnosis of pericardial effusion in patients who arrest after cardiac surgery.